Mar 14,2022

Predicting Glycated Hemoglobin Through Continuous Glucose Monitoring in Real-Life Conditions: Improved Estimation Methods

The adoption of continuous glucose monitoring (CGM) already helps to improve glycemic control in diabetes. When coupled with appropriate data analysis techniques, CGM also provides dependable estimates for significant metrics, like glycated hemoglobin (HbA1c).

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Mar 14,2022

Health2Sync partners with Novo Nordisk to support better insulin usage

Taiwanese chronic disease management company Health2Sync has entered into a partnership with Danish pharmaceutical firm Novo Nordisk to help patients undergoing insulin therapy wirelessly transfer dose logs to a mobile health app. The Health2Sync mobile app is now able to sync patients' dose logs, including time and dosage per injection, from the newly released NovoPen 6 and NovoPen Echo Plus that have been powered by near-field communication.

COLLABORATION PARTNERSHIP

#connected device

#mobile app

#insulin pen

View Analyst & Ambassador Comments
Go to original news
Mar 14,2022

Dexcom G7 Receives CE Mark – Next-Generation Continuous Glucose Monitoring System to Revolutionize Diabetes Management

DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today it has secured CE Mark for the Dexcom G7 Continuous Glucose Monitoring (CGM) System for people with diabetes in Europe age two years and older, including pregnant women.

REGULATORY CE MARK

#cgm

View Analyst & Ambassador Comments
Go to original news
Mar 14,2022

First Mile Care Appoints Healthcare Veteran Salvatore Boscarino Chief Commercial Officer

First Mile Care (www.firstmilecare.com), a preventative chronic care company whose mission is to halve the number of Americans with type 2 diabetes by 2028, has expanded its executive team to include Salvatore Boscarino in the new role of Chief Commercial Officer (CCO).

View Analyst & Ambassador Comments
Go to original news
Mar 15,2022

Better Therapeutics Announces Positive Primary Endpoint Data From Pivotal Clinical Trial of BT-001, a Prescription Digital Therapeutic (PDT) for Patients With Uncontrolled Type 2 Diabetes

Better Therapeutics, Inc., a prescription digital therapeutics company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced primary endpoint data from its pivotal trial of BT-001, a first-in-class investigational PDT platform that is designed to use digitally delivered nCBT to treat type 2 diabetes.

CLINICAL STUDY

#dtx

View Analyst & Ambassador Comments
Go to original news
Mar 15,2022

National Quality Initiatives Amplify Health Systems’ Focus on Effective Glycemic Management as Glytec Fortifies Industry Leadership Position

Glytec, the only provider of cloud-based insulin management software across the continuum of care, today announced that it has significantly expanded the deployment of its eGlycemic Management System® (eGMS) over the past 12 months to address the mounting need for effective, innovative and data-driven glycemic management support solutions.

PRODUCT
View Analyst & Ambassador Comments
Go to original news
Mar 16,2022

Diabetes tech is off to a hot start in 2022

Change is continuous in continuous glucose monitoring (GCM), with expanded wear-times, improved accuracy and more. Meanwhile, never-ending innovation in insulin delivery is delivering wearable patches and closedloop delivery systems, making insulin management easier for people with diabetes.

#cgm

#insulin pump

#closed loop

View Analyst & Ambassador Comments
Go to original news
Mar 16,2022

Glooko acquires Diabnext and its digital health platform for managing diabetes

Glooko announced today that it acquired Diabnext, a developer of a digital health platform for managing diabetes and connecting to healthcare providers. Paris-based Diabnext’s mobile app tracks diabetes data so that physicians can collaborate with their patients to monitor individual patient data and provide remote care. Financial details of the acquisition were not disclosed. Diabnext’s platform will be marketed under the name “Glooko XT.”

COLLABORATION MERGERS & ACQUISITION

#product & service

#mobile app

View Analyst & Ambassador Comments
Go to original news
Mar 16,2022

BioCoach Reaches $100 Million Valuation for Its Innovative Approach to Digital Health Solutions

BioCoach, a leader in direct-to-consumer in-vitro diagnostic testing, today announced it has received $4 million in funding from SecretLab LLC. BioCoach recently received FDA 510 (k) clearance for a next-generation glucose and ketone monitoring system.

FUNDING SEED ROUND
View Analyst & Ambassador Comments
Go to original news
Mar 17,2022

Medtronic names new presidents for diabetes, surgical robotics, cardiac rhythm units

Medtronic (NYSE:MDT) is making leadership changes in its diabetes, surgical robotics and cardiac rhythm management operating units, the company said today. Que Dallara joins the medtech giant as EVP and president of the diabetes business.

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES